查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370887

狼疮治疗市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按治疗类型、给药途径、最终用户、地区、竞争细分

Lupus Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Treatment Type, By Route of Administration, By End User, By Region, By Competition
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

预计全球狼疮治疗市场在 2024-2028 年预测期内将出现强劲成长。全球狼疮治疗市场的主要驱动力之一是该疾病盛行率的不断上升。当人体的免疫系统攻击自身的组织和器官时，就会引发自体免疫疾病狼疮。狼疮相关发炎会影响多种身体功能，包括关节、皮肤、肾臟、血球、大脑、心臟和肺部。由于狼疮的征兆和症状与其他疾病相似，因此诊断起来很困难。在许多（但不是全部）狼疮病例中，最明显的狼疮症状是脸部皮疹，看起来像蝴蝶翅膀在双颊上展开。有些人从出生就容易罹患狼疮，这可能是由疾病、药物甚至阳光引起的。据美国狼疮基金会称，全世界至少有 500 万人患有某种形式的狼疮，并且这种疾病在 15-44 岁年龄层的人群中更为普遍。

狼疮盛行率的增加推动了狼疮治疗市场的成长

市场概况
预测期 2024-2028
2022 年市场规模 20.5亿美元
2028 年市场规模 28.9亿美元
2023-2028 年复合年增长率 5.84%
成长最快的细分市场 医院和诊所
最大的市场 北美洲

由于全球狼疮病例不断增加，狼疮治疗市场预计将成长。狼疮盛行率上升的原因尚不完全清楚，但研究已经确定了几个潜在因素。根据美国狼疮基金会的数据，每 10 名患有狼疮的成年人中有 9 名是女性。关键因素之一是遗传。研究表明，某些遗传变异会增加罹患狼疮的风险。例如，具有 IRF5 基因特定变异的人更有可能患上狼疮。然而，仅靠遗传学无法解释狼疮盛行率的增加。环境因素也扮演重要角色。污染、毒素和传染源等环境因素与狼疮的发生有关。接触某些化学物质和污染物（例如二氧化硅）已被证明会增加罹患狼疮的风险，从而导致全球狼疮治疗市场的扩大。此外，EB病毒和鉅细胞病毒等感染也与狼疮的发病有关。生活方式和饮食的改变也可能导致狼疮盛行率上升。根据一篇研究文章“系统性红斑狼疮的全球流行病学：全面的系统分析和建模研究”，系统性红斑狼疮（SLE）是最常见的狼疮类型。一般人群中 SLE 的发生率从中亚每 10 万人年 1.18（0.16 至 3.68）到中欧每 10 万人年 13.74（3.2 至 31.82）不等。 SLE 发生率估计最高的四个国家是波兰，其次是美国、巴贝多和中国。加工食品含量高、营养成分含量低的饮食会增加体内炎症，进而引发狼疮等自体免疫疾病。此外，久坐的生活方式和肥胖与患狼疮的风险增加有关，预计这将扩大全球狼疮治疗市场。据世界心臟联合会称，到 2025 年，可能有 27 亿成年人超重或肥胖。

药物发现的不断增长的研究和开发推动了全球狼疮治疗市场

狼疮是一种复杂的疾病，会影响身体的各个部位，例如皮肤、关节、肾臟和肺部。虽然有治疗方法可以控制狼疮症状，但无法治癒。因此，增加狼疮治疗的研发（R＆D）工作对于改善患者的治疗结果和生活品质并导致全球狼疮治疗市场的成长至关重要。开发狼疮新疗法的主要挑战之一是疾病的复杂性。狼疮是一种多因素疾病，这意味着有许多因素导致其发生和进展。这些因素包括遗传、环境和荷尔蒙因素。儘管面临挑战，近年来人们对开发狼疮新疗法的兴趣日益浓厚。原因之一是人们对该疾病的潜在机制的了解不断加深。基因研究和技术的进步使研究人员能够识别出参与狼疮发生和进展的特定基因和途径。这些知识导致了针对这些特定基因和途径的新药的开发。人们对狼疮治疗越来越感兴趣的另一个原因是对新疗法的需求不断增长。虽然目前有针对狼疮的治疗方法，但它们并不总是对所有患者有效，而且许多方法都有明显的副作用。因此，需要新的和改进的疗法来有效控制狼疮症状，同时最大限度地减少副作用，从而促进全球狼疮治疗市场的成长。研究人员和产业之间的合作有助于弥合基础研究和临床开发之间的差距，并加速新疗法的开发。透过共同努力，研究人员利用业界的专业知识和资源来开发新的药物和疗法，从而导致全球对狼疮治疗的巨大需求。除了资金和合作之外，还可以利用技术进步来增加狼疮治疗的研发工作。例如，人工智慧和机器学习的进步有助于识别新的药物标靶并加速药物发现过程。同样，基因编辑和基因治疗的进步有助于开发更有针对性和个人化的狼疮疗法，预计这将推动全球狼疮治疗市场的成长。截至 2023 年 5 月 9 日，根据 ClinicalTrials.gov，全球约有 278 项与狼疮治疗相关的研究处于不同的开发阶段。

合併、收购与合作

2021 年 6 月，Progentec 与葛兰素史克 (GlaxoSmithKline, plc) 合作签订了一项为期 18 个月的协议，研究新的系统性红斑狼疮 (SLE 或狼疮) 测量和管理工具。

2023年1月，EVOQ Therapeutics 与吉利德科学公司启动了合作和授权协议，以推进后者的技术并创造治疗狼疮的免疫疗法。根据协议条款，两家公司将合作推进 RA 和狼疮免疫疗法的临床前开发。

市场区隔

全球狼疮治疗市场根据治疗类型、给药途径和最终用户进行细分。根据治疗类型，全球狼疮治疗市场分为非类固醇抗发炎药、皮质类固醇、抗疟药、免疫抑制剂、生物製剂和其他。根据给药途径，全球狼疮治疗市场分为口服、静脉注射和皮下注射。根据最终用户，全球狼疮治疗市场分为医院和诊所、门诊护理中心和其他。

市场参与者

葛兰素史克公司、诺华公司、阿斯特捷利康公司、罗氏公司、礼来公司。 ImmuPharma PLC、辉瑞公司、赛诺菲公司、百时美施贵宝公司、默克公司是全球狼疮治疗市场的主要参与者。

报告范围：

在本报告中，除了以下详细介绍的产业趋势外，全球狼疮治疗市场也分为以下几类：

狼疮治疗市场，依治疗类型：

  • 非类固醇抗发炎药
  • 皮质类固醇
  • 抗疟药
  • 免疫抑制剂
  • 生物製剂
  • 其他的

狼疮治疗市场，依给药途径：

  • 口服
  • 静脉
  • 皮下

狼疮治疗市场，依最终用户划分：

  • 医院和诊所
  • 门诊护理中心
  • 其他的

狼疮治疗市场，按地区：

  • 欧洲
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙
  • 亚太
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 中东和非洲
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非
  • 土耳其

竞争格局

  • 公司概况：全球狼疮治疗市场主要公司的详细分析。

可用的客製化：

  • 根据给定的市场资料，TechSci Research 可根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：COVID-19 对全球狼疮治疗市场的影响

第 6 章：临床试验分析

  • 正在进行的临床试验
  • 已完成的临床试验
  • 终止的临床试验
  • 按开发阶段分類的管道细目
  • 管道细分（按状态）
  • 按研究类型分類的管道细目
  • 按地区分類的管道明细
  • 临床试验热图

第 7 章：全球狼疮治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依治疗类型（非类固醇抗发炎药、皮质类固醇、抗疟药、免疫抑制剂、生物製剂、其他）
    • 依给药途径（口服、静脉注射、皮下注射）
    • 按最终使用者（医院和诊所、门诊护理中心、其他）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图
    • 按治疗类型
    • 依给药途径
    • 按最终用户
    • 按地区

第 8 章：北美狼疮治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按治疗类型
    • 依给药途径
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 9 章：欧洲狼疮治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按治疗类型
    • 依给药途径
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利

第 10 章：亚太地区狼疮治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按治疗类型
    • 依给药途径
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 11 章：南美洲狼疮治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按治疗类型
    • 依给药途径
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 12 章：中东和非洲狼疮治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按治疗类型
    • 依给药途径
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非狼疮治疗公司
    • 沙乌地阿拉伯狼疮治疗公司
    • 阿联酋狼疮治疗公司
    • 土耳其狼疮治疗

第 13 章：市场动态

  • 司机
  • 挑战

第 14 章：市场趋势与发展

  • 产品发布
  • 併购
  • 最近的发展

第 15 章：全球狼疮治疗市场：SWOT 分析

第16章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第17章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（上市公司）
  • 最近的发展
  • SWOT分析
    • GlaxoSmithKline, plc.
    • Novartis AG
    • AstraZeneca, plc.
    • F. Hoffmann-La Roche AG
    • Eli Lilly and Company
    • ImmuPharma PLC
    • Pfizer, Inc.
    • Sanofi SA
    • Bristl Myers Squibb Company
    • Merck & Co., Inc.

第 18 章：策略建议

第 19 章：关于我们与免责声明

简介目录
Product Code: 15074

Global Lupus Therapeutics Market is anticipated to witness formidable growth in the forecast period, 2024-2028. One of the key drivers of the global lupus therapeutics market is the increasing prevalence of the disease. The autoimmune disease lupus is brought on when the body's immune system attacks its own tissues and organs. Lupus-related inflammation can impact a variety of bodily functions, including joints, skin, kidneys, blood cells, brain, heart, and lungs. Because of how frequently its signs and symptoms resemble those of other illnesses, lupus can be challenging to diagnose. In many but not all cases of lupus, the most recognizable lupus symptom is a facial rash that looks like butterfly wings unfolding across both cheeks. Some people are predisposed to lupus from birth, which can be brought on by illnesses, medications, or even sunlight. According to Lupus Foundation of America, at least five million people worldwide have a form of lupus and the disease is more prevalent among the people belonging to age group 15-44.

Lupus has no known cure, but treatments can help manage symptoms. The market for lupus therapeutics is also being driven by advancements in technology and the development of new drugs. There are currently only a few FDA-approved drugs for the treatment of lupus, but there are many promising drugs in the pipeline, propelling the growth of Global Lupus Therapeutics Market. In addition to traditional pharmaceuticals, there are also emerging therapies for lupus, such as gene therapy and stem cell therapy. These therapies have the potential to provide long-term relief from lupus symptoms and could be a game-changer in the treatment of the disease, leading to the expansion of Global Lupus Therapeutics Market. Apart from these, favorable government policies for developing Lupus Therapeutics and technological advancement for new applications propel the Global Lupus Therapeutics Market in the forecasted period. While there is currently no cure for lupus, several therapies are available to manage symptoms and prevent complications. The choice of therapy depends on the patient's symptoms, medical history, and other factors which are expected to grow Global Lupus Therapeutics Market.

Increasing Prevalence of Lupus propels the market growth for Lupus Therapeutics

Market Overview
Forecast Period2024-2028
Market Size 2022USD2.05 Billion
Market Size 2028USD2.89 Billion
CAGR 2023-20285.84%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

The market for Lupus Therapeutics is anticipated to grow due to the rising cases of Lupus worldwide. The reasons behind the rising prevalence of lupus are not yet fully understood, but research has identified several potential factors. According to Lupus Foundation of America, 9 out of 10 adults who are suffering from lupus are women. One of the key factors is genetics. Studies have shown that certain genetic variations can increase the risk of developing lupus. For example, people with a specific variation in the gene known as IRF5 are more likely to develop lupus. However, genetics alone cannot explain the increasing prevalence of lupus. Environmental factors also play a significant role. Environmental factors such as pollution, toxins, and infectious agents have been linked to the development of lupus. Exposure to certain chemicals and pollutants, such as silica, has been shown to increase the risk of developing lupus, leading to the expansion of Global Lupus Therapeutics Market. Additionally, infections such as Epstein-Barr virus and cytomegalovirus have been linked to the onset of lupus. Changes in lifestyle and diet may also be contributing to the rising prevalence of lupus. According to a research article, "Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study", Systemic lupus erythematosus (SLE), is the most common type of lupus. The incidence of SLE in the general population varied from 1.18 (0.16 to 3.68) per 100 000 person-years in central Asia to 13.74 (3.2 to 31.82) per 100 000 person-years in central Europe. The top four countries with the highest estimates of SLE incidence were Poland followed by United States, Barbados, and China. A diet high in processed foods and low in nutrients can increase inflammation in the body, which can trigger autoimmune diseases such as lupus. Additionally, sedentary lifestyles and obesity have been linked to an increased risk of developing lupus, which is expected to expand Global Lupus Therapeutics Market. According to the World Heart Federation, by 2025, 2.7 billion adults might be overweight or obese.

Rising Research and Development in Drug Discovery drives Global Lupus Therapeutics Market

Lupus is a complex disease that can affect various parts of the body, such as the skin, joints, kidneys, and lungs. While there are treatments available to manage the symptoms of lupus, there is no cure. Therefore, increasing research and development (R&D) efforts for lupus therapeutics is crucial to improve patient outcomes and quality of life and leading to the growth of Global Lupus Therapeutics Market. One of the main challenges in developing new therapeutics for lupus is the complex nature of the disease. Lupus is a multifactorial disease, meaning that there are many factors that contribute to its development and progression. These factors include genetic, environmental, and hormonal factors. Despite the challenges, there has been a growing interest in developing new therapeutics for lupus in recent years. One reason for this is the increasing understanding of the underlying mechanisms of the disease. Advances in genetic research and technology have allowed researchers to identify specific genes and pathways that are involved in the development and progression of lupus. This knowledge has led to the development of new drugs that can target these specific genes and pathways. Another reason for the increasing interest in lupus therapeutics is the growing demand for new treatments. While there are currently treatments available for lupus, they are not always effective for all patients, and many have significant side effects. Therefore, there is a need for new and improved therapies that can effectively manage the symptoms of lupus while minimizing side effects, hence augmenting the growth of Global Lupus Therapeutics Market. Collaboration between researchers and industry helps bridge the gap between basic research and clinical development and accelerate the development of new therapeutics. By working together, researchers leverage the expertise and resources of industry to develop new drugs and therapies leading to the huge demand for lupus therapeutics globally. In addition to funding and collaboration, there are also technological advancements that are leveraged to increase R&D efforts for lupus therapeutics. For example, advances in artificial intelligence and machine learning help to identify new drug targets and accelerate the drug discovery process. Similarly, advances in gene editing and gene therapy have helped in the development of more targeted and personalized therapies for lupus, which is expected to propel the growth of Global Lupus Therapeutics Market. As of 9th May 2023, as per clinicaltrials.gov, there are around 278 studies in different phases of development related to Lupus Therapeutics worldwide.

Mergers, Acquisitions and Collaborations

In June 2021, Progentec collaborated with GlaxoSmithKline, plc for an 18-month agreement to research new systemic lupus erythematosus (SLE or lupus) measurement and management tools.

In January 2023, EVOQ Therapeutics launched its collaboration and licensing agreement with Gilead Sciences to advance the latter's technology and create immunotherapies for the treatment of lupus. In accordance with the terms of the agreement, the two businesses will collaborate to advance the preclinical development of immunotherapies for RA and lupus.

Market Segmentation

Global Lupus Therapeutics Market is segmented based on Treatment Type, Route of Administration and End-User. Based on Treatment Type, the global lupus therapeutics market is divided into NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics and Others. Based on Route of Administration, the global lupus therapeutics market is divided into Oral, Intravenous and Subcutaneous. Based on End-User, the global lupus therapeutics market is divided into Hospitals & Clinics, Ambulatory Care Centers and Others.

Market players

GlaxoSmithKline, plc., Novartis AG, AstraZeneca, plc., Hoffmann-La Roche AG, Eli Lilly and Company. ImmuPharma PLC, Pfizer, Inc., Sanofi S.A., Bristl Myers Squibb Company, Merck & Co., Inc. are the key players operating in the global lupus therapeutics market.

Report Scope:

In this report, Global Lupus Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Lupus Therapeutics Market, By Treatment Type:

  • NSAIDs
  • Corticosteroids
  • Antimalarials
  • Immunosuppressants
  • Biologics
  • Others

Lupus Therapeutics Market, By Route of Administration:

  • Oral
  • Intravenous
  • Subcutaneous

Lupus Therapeutics Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Lupus Therapeutics Market, By region:

  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • North America
  • United States
  • Canada
  • Mexico
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Turkey

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in Global Lupus Therapeutics Market.

Available Customizations:

  • With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Impact of COVID-19 on Global Lupus Therapeutics Market

6. Clinical Trial Analysis

  • 6.1. Ongoing Clinical Trials
  • 6.2. Completed Clinical Trials
  • 6.3. Terminated Clinical Trials
  • 6.4. Breakdown of Pipeline, By Development Phase
  • 6.5. Breakdown of Pipeline, By Status
  • 6.6. Breakdown of Pipeline, By Study Type
  • 6.7. Breakdown of Pipeline, By Region
  • 6.8. Clinical Trials Heat Map

7. Global Lupus Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics, Others)
    • 7.2.2. By Route of Administration (Oral, Intravenous, Subcutaneous)
    • 7.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 7.2.4. By Region
    • 7.2.5. By Company (2022)
  • 7.3. Market Map
    • 7.3.1. By Treatment Type
    • 7.3.2. By Route of Administration
    • 7.3.3. By End User
    • 7.3.4. By Region

8. North America Lupus Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Lupus Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By End User
    • 8.3.2. Canada Lupus Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By End User
    • 8.3.3. Mexico Lupus Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By End User

9. Europe Lupus Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. Germany Lupus Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By End User
    • 9.3.2. France Lupus Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By End User
    • 9.3.3. United Kingdom Lupus Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By End User
    • 9.3.4. Spain Lupus Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Treatment Type
        • 9.3.4.2.2. By Route of Administration
        • 9.3.4.2.3. By End User
    • 9.3.5. Italy Lupus Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Treatment Type
        • 9.3.5.2.2. By Route of Administration
        • 9.3.5.2.3. By End User

10. Asia-Pacific Lupus Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Lupus Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By End User
    • 10.3.2. India Lupus Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By End User
    • 10.3.3. Japan Lupus Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By End User
    • 10.3.4. South Korea Lupus Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Treatment Type
        • 10.3.4.2.2. By Route of Administration
        • 10.3.4.2.3. By End User
    • 10.3.5. Australia Lupus Therapeutics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Treatment Type
        • 10.3.5.2.2. By Route of Administration
        • 10.3.5.2.3. By End User

11. South America Lupus Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Treatment Type
    • 11.2.2. By Route of Administration
    • 11.2.3. By End User
    • 11.2.4. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Lupus Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Treatment Type
        • 11.3.1.2.2. By Route of Administration
        • 11.3.1.2.3. By End User
    • 11.3.2. Argentina Lupus Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Treatment Type
        • 11.3.2.2.2. By Route of Administration
        • 11.3.2.2.3. By End User
    • 11.3.3. Colombia Lupus Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Treatment Type
        • 11.3.3.2.2. By Route of Administration
        • 11.3.3.2.3. By End User

12. Middle East and Africa Lupus Therapeutics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Treatment Type
    • 12.2.2. By Route of Administration
    • 12.2.3. By End User
    • 12.2.4. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Lupus Therapeutics Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Treatment Type
        • 12.3.1.2.2. By Route of Administration
        • 12.3.1.2.3. By End User
    • 12.3.2. Saudi Arabia Lupus Therapeutics Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Treatment Type
        • 12.3.2.2.2. By Route of Administration
        • 12.3.2.2.3. By End User
    • 12.3.3. UAE Lupus Therapeutics Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Treatment Type
        • 12.3.3.2.2. By Route of Administration
        • 12.3.3.2.3. By End User
    • 12.3.4. Turkey Lupus Therapeutics Market Outlook
      • 12.3.4.1. Market Size & Forecast
        • 12.3.4.1.1. By Value
      • 12.3.4.2. Market Share & Forecast
        • 12.3.4.2.1. By Treatment Type
        • 12.3.4.2.2. By Route of Administration
        • 12.3.4.2.3. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

  • 14.1. Product Launches
  • 14.2. Mergers & Acquisitions
  • 14.3. Recent Developments

15. Global Lupus Therapeutics Market: SWOT Analysis

16. Porter's Five Forces Analysis

  • 16.1. Competition in the Industry
  • 16.2. Potential of New Entrants
  • 16.3. Power of Suppliers
  • 16.4. Power of Customers
  • 16.5. Threat of Substitute Products

17. Competitive Landscape

  • 17.1. Business Overview
  • 17.2. Company Snapshot
  • 17.3. Products & Services
  • 17.4. Financials (In case of listed companies)
  • 17.5. Recent Developments
  • 17.6. SWOT Analysis
    • 17.6.1. GlaxoSmithKline, plc.
    • 17.6.2. Novartis AG
    • 17.6.3. AstraZeneca, plc.
    • 17.6.4. F. Hoffmann-La Roche AG
    • 17.6.5. Eli Lilly and Company
    • 17.6.6. ImmuPharma PLC
    • 17.6.7. Pfizer, Inc.
    • 17.6.8. Sanofi S.A.
    • 17.6.9. Bristl Myers Squibb Company
    • 17.6.10. Merck & Co., Inc.

18. Strategic Recommendations

19. About Us & Disclaimer